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MaOBJECTIVES This study sought to evaluate differential effects of visceral fat (VF) and subcutaneous fat andtheir effects on metabolic syndrome (MetS) risk across body mass index (BMI) categories.BACKGROUND The regional distribution of adipose tissue is an emerging risk factor for cardiometabolicdisease, although serial changes in fat distribution have not been extensively investigated. VF and its alterations over
time may be a better marker for risk than BMI in normal weight and overweight or obese individuals.METHODS We studied 1,511 individuals in the MESA (Multi-Ethnic Study of Atherosclerosis) with adiposityassessment by computed tomography (CT). A total of 253 participants without MetS at initial scan underwent repeat CT
(median interval 3.3 years). We used discrete Cox regression with net reclassiﬁcation to investigate whether baseline and
changes in VF area are associated with MetS.RESULTS Higher VF was associated with cardiometabolic risk and coronary artery calciﬁcation, regardless ofBMI. After adjustment, VF was more strongly associated with incident MetS than subcutaneous fat regardless of weight,
with a 28% greater MetS hazard per 100 cm2/m VF area and signiﬁcant net reclassiﬁcation (net reclassiﬁcation index:
0.44, 95% conﬁdence interval [CI]: 0.29 to 0.60) over clinical risk. In individuals with serial imaging, initial VF (hazard
ratio: 1.24 per 100 cm2/m, 95% CI: 1.08 to 1.44 per 100 cm2/m, p ¼ 0.003) and change in VF (hazard ratio: 1.05 per 5%
change, 95% CI: 1.01 to 1.08 per 5% change, p ¼ 0.02) were associated with MetS after adjustment. Changes in sub-
cutaneous fat were not associated with incident MetS after adjustment for clinical risk and VF area.CONCLUSIONS VF is modestly associated with BMI. However, across BMI, a single measure of and longitu-dinal change in VF predict MetS, even accounting for weight changes. Visceral adiposity is essential to assessing cardi-
ometabolic risk, regardless of age, race, or BMI, and may serve as a marker and target of therapy in cardiometabolic
disease. (J Am Coll Cardiol Img 2014;7:1221–35) © 2014 by the American College of Cardiology Foundation.V isceral adipose tissue is a relevant, pro-inﬂammatory endocrine tissue and may ac-count for an increased cardiometabolic risk
across body mass index (BMI) (1). A recent report in
obese individuals demonstrated that a single mea-
surement of visceral fat (VF) was associated with
risk of dysglycemia, independent of weight or meta-
bolic risk (2). Visceral adiposity is associated
with an adverse cardiometabolic proﬁle, including
inﬂammation, insulin resistance, and myocardialeived materials for investigator-initiated research from Amneal Pharmac
., and Mercodia; and has served as a consultant to Novo Nordisk. Dr
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phenotype—regardless of adiposity status (1). Never-
theless, several questions critical to using BMI and
adiposity in cardiovascular risk remain. Whether
standard metrics of adiposity used in the clinic
(weight or BMI and waist circumference) adequately
reﬂect pathologic visceral (or subcutaneous) fat and
the subsequent risk of metabolic syndrome (MetS) is
important. Whether weight gain alone explains most
of the hazard of incident MetS—regardless of whethereuticals, Johnson & Johnson, Novo Nordisk, Nestle
. Allison was supported by funding for the MESA
ng, and Blood Institute (R01-HL088451). All other
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BMI = body mass index
CT = computed tomography
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1223it is gained in the visceral or subcutaneous depot—
will not only provide valuable translation of the mo-
lecular and physiological importance of visceral
adiposity, but will also inform clinical assessments
of risk with weight reduction.FIGURE 1 Diagram of Visceral and Subcutaneous Fat
Compartments Analyzed by CT Imaging in MESA
A description of the delineation of these compartments is pro-
vided in the text. CT ¼ computed tomography; MESA ¼ Multi-
Ethnic Study of Atherosclerosis.
SEE PAGE 1236
HR = hazard ratio
MetS = metabolic syndrome
SQ = subcutaneous fat
visceral fatTo date, most reports on large, community-based
studies have used a single measure of VF to fore-
cast long-term risk (2–4) or are limited to 1 ethnic
background (5,6). Here, we address this im-
portant gap by studying participants in MESA
(Multi-Ethnic Study of Atherosclerosis) with VF
measures at 2 time points and detailed metabolic,
cardiac, and demographic phenotyping. We deﬁne a
relationship between visceral and subcutaneous
adiposity and BMI, their cross-sectional association
with incident MetS across BMI categories and race
independent of classic cardiometabolic risk factors,
and the longitudinal association of changes in each
fat depot versus changes in weight with incident
MetS.
METHODS
PARTICIPANT POPULATION. The overall design of
the MESA study has been described previously (7). In
brief, the MESA study consists of 6,814 men and
women of different ethnicities (white, African Amer-
ican, Chinese American, and Hispanic) enrolled from
6 different national sites, all of whom were free of
clinical cardiovascular disease (history of myocardial
infarction, angina pectoris, prior revascularization,
heart failure, atrial ﬁbrillation, stroke, or peripheral
arterial disease) at the time of enrollment.
Baseline demographics, medical history (including
cardiac risk factors), medications (for hypertension,
dyslipidemia, and diabetes), and physical examina-
tion were assessed at 5 clinic visits in MESA (exami-
nations 1 to 5, between 2000 and 2011), as has been
described (8). MetS was determined at each MESA
clinic visit as deﬁned by updated National Cholesterol
Education Panel Adult Treatment Panel III guidelines
(including abdominal obesity by waist circumference,
serum triglyceride level, high-density lipoprotein
[HDL] cholesterol, systolic and diastolic blood pres-
sure, and fasting glucose) (9).
At examinations 2 and 3, a random subset of 1,970
MESA participants underwent abdominal computed
tomography (CT) scans for aortic calcium that were
subsequently used for quantifying visceral/subcu-
taneous fat mass: examination 2: n ¼ 756/n ¼ 577;
examination 3: n ¼ 1,172/n ¼ 1,114, respectively. For
the purposes of the current study, we deﬁned the“baseline” examination as the ﬁrst examina-
tion at which the CT scan was performed
(either examination 2 or 3). Of this initial
cohort with both baseline subcutaneous and
VF data (n ¼ 1,687), we excluded participants
with: 1) missing data for BMI at baseline ex-
amination (n¼ 1); or 2) any history of cirrhosis,
cancer, or self-reported renal disease at index
examination (to limit confounding by chronic
illness and inﬂammation; n ¼ 175). The ﬁnal popula-
tion was composed of 1,511 individuals with baseline
measures for visceral adiposity. Of this subcohort, 253
participants without MetS or dysglycemia (impaired
fasting glucose $100 mg/dl or diabetes) at baseline
were reimaged at examination 4 (median interval 3.2
years, interquartile range [IQR]: 3.0 to 3.3 years) and
had complete data for subcutaneous and visceral
adiposity.
Fasting blood samples collected at examination 3
were used to quantify selected adipokines reﬂecting
insulin resistance and systemic inﬂammation (inter-
leukin-6, high-sensitivity C-reactive protein [CRP],
leptin, adiponectin, insulin, and tumor necrosis fac-
tor-a) as previously described (10,11). Protocols were
approved by the Institutional Review Board at each
participating institution. All participants provided
written informed consent.
MEASUREMENT OF VISCERAL AND SUBCUTANEOUS
ADIPOSITY. Electron-beam CT scanners were utilized
at Northwestern University and University of Cali-
fornia, Los Angeles (Imatron C-150, Imatron Inc.,
South San Francisco, California), with the following
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1225settings: collimation 3 mm, slice thickness 6 mm,
reconstruction using 25 6-mm slices with 35-cm ﬁeld
of view and normal kernel. Multidetector CT scanners
were utilized at Columbia University, Wake Forest
University, and University of Minnesota ﬁeld centers
(Sensation 64 [Siemens, Malvern, Pennsylvania] and
GE Lightspeed [GE Healthcare, Waukesha, Wiscon-
sin], Siemens S4 Volume Zoom, and Siemens Sensa-
tion 16, respectively). CT imaging was interpreted
blinded to clinical information.
For abdominal visceral and subcutaneous fat areas,
slices centered at the L4–L5 disc spaces were selected.
Visceral adiposity (Figure 1) was deﬁned as the fat
enclosed by the visceral cavity. Subcutaneous adipo-
sity was deﬁned as the fat outside of the visceral
cavity but did not include that located within the
muscular fascia. Fat tissue was identiﬁed as being
between 190 and 30 Hounsﬁeld units. Within each
area of interest (subcutaneous and visceral), we
assigned the density value assigned to each pixel
using the MIPAV 4.1.2 software (National Institutes of
Health, Bethesda, Maryland) as fat or lean tissue,
calculating the total visceral and abdominal fat area
(in terms of cm2). Six transverse cross-sectional slices
of data were analyzed (2 at L2–3, 2 at L3–4, and 2 at
L4–5). Two subjects had only 5 slices scored due to
problems with the location where the scan was per-
formed on the body. These 2 subjects were excluded
as they also lacked subcutaneous fat data. To calcu-
late visceral and subcutaneous fat area, we calculated
the sum of visceral and subcutaneous fat area over all
6 available slices. Fat area was indexed to height
(in meters). Inter-rater and intrarater reliabilities for
total abdominal, subcutaneous, and visceral cavity
areas were 0.99 for all measures.
Due to the size of the ﬁeld of view used for the CT
imaging, the positioning of the subject in the scanner,
or the size of the subject, parts of the abdomen for
some subjects was outside of the ﬁeld of view and the
affected anatomic data could not be processed. In
these cases, different measures of imputation for
missing data (described in detail in the Online
Appendix) were employed to estimate the missing
data for subcutaneous fat (n ¼ 312, 20.7%) using
prediction equations (n ¼ 69, 4.6%) or the “half-
abdomen” method (n ¼ 292, 19.3%). For 3 subjects,
VF was imputed using the “modiﬁed” method. De-
scriptions of these methods are provided in the Online
Appendix (additional detail available on request).
Of note, different imputation methods could be used
for different slices from a single patient, depending
on the type of image artifacts present.
STATISTICAL ANALYSIS. All variables were exam-
ined for normality, and parametric or nonparametric
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1226tests were selected as appropriate. Visceral and sub-
cutaneous adipose burden were dichotomized at
their respective medians. To investigate the clinical
impact of VF in different BMI categories, we stratiﬁed
BMI into 3 levels corresponding to normal weight (<25
kg/m2), overweight (25 to 30 kg/m2), and obese (>30
kg/m2). We compared clinical, laboratory, and imag-
ing ﬁndings between those with above versus below
median visceral adipose in each category of obesity
using Wilcoxon rank-sum tests. We calculated
Spearman correlation coefﬁcients to measure the
association between visceral and subcutaneous fat
area and BMI or weight, as well as the change in fatLow Visceral Adiposity
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FIGURE 2 Evolution of Metabolic Risk Factors From Index MESA Ex
to More Follow-Up Study Visits
Higher visceral adiposity was associated with worse risk factor proﬁle (p
(BP) and glucose control worsened (p ¼ 0.04 and p < 0.0001, respect
improved over time (p ¼ 0.0001 and p < 0.0001). There was no evidenc
fat, except for triglycerides (interaction p ¼ 0.004). All analyses were p
random intercepts. Abbreviations as in Figure 1.depots with changes in BMI or weight. We used
discrete-time Cox regression to specify incremental
multivariable survival models assessing the additive
value of clinical risk factors, MetS components, and
visceral and subcutaneous fat burden on hazard of
incident MetS. Of note, as a result of participants be-
ing imaged at examination 2 or 3 as baseline, regres-
sions for MetS had a limited cohort at examination 3
(e.g., only those imaged on examination 2 would be
eligible for developing MetS at examination 3).
To address the association of changes in VF mea-
sures with incident MetS, we performed a similar
incremental survival analysis among subjects withHigh Visceral Adiposity
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erformed with longitudinal mixed effect models with per subject
Continued on the next page
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1227repeated VF measures, adjusted for clinical, demo-
graphic, and cardiometabolic risk. Multicollinearity
was addressed by examination of hazard ratios (HRs) in
incremental survival analysis to ensure stability. We
purposefully included the individual components of
MetS in the regression for MetS to afford the greatest
statistical barrier for adiposity measures to achieve
signiﬁcant association with MetS. Effect modiﬁcation
for age (dichotomized around median in MESA), sex,
and race was measured in all models. Direct adjusted
survival curves from the ﬁnal Coxmodels were used to
visualize survival free of MetS across follow-up ex-
aminations (12). C-index, integrated discrimination
improvement, and net reclassiﬁcation improvement
were assessed (13). Because there are no widely
accepted risk categories for incident MetS, the
continuous net reclassiﬁcation index was used. SAS
(version 9.4, SAS Institute, Cary, North Carolina) and R
(version 3.0.2, R Foundation for Statistical Computing,
Vienna, Austria) were used for all analyses. A 2-sided
p value <0.05 was considered statistically signiﬁcant.Low Visceral Adiposity
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VISCERAL ADIPOSITY IDENTIFIES AN ADVERSE CARDIO-
METABOLIC PROFILE IN BOTH NORMAL WEIGHT AND
OVERWEIGHT/OBESE INDIVIDUALS. Demographic, clin-
ical, and biochemical characteristics of our study
population stratiﬁed by World Health Organization
BMI categories (normal <25 kg/m2; overweight 25 to
30 kg/m2; obese >30 kg/m2) and by median height-
indexed visceral adipose tissue mass (500.2 cm2/m)
are shown in Table 1. In each BMI category, in-
dividuals with above-median visceral adiposity were
older, were more frequently male, and had greater
cardiometabolic risk. In addition, individuals with a
normal BMI but higher visceral adiposity had higher
glucose (p < 0.0001), lower adiponectin (p < 0.0001),
higher high-sensitivity CRP (p ¼ 0.02), and higher
insulin (p<0.0001), a biochemical phenotype similar
to overweight/obese individuals (1). Similar asso-
ciations were observed in overweight/obese in-
dividuals. In addition, there was a trend towardHigh Visceral Adiposity
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1228progressively lower adiponectin, higher high-
sensitivity CRP and interleukin-6, and higher in-
sulin with higher weight categories. Finally, MESA
participants with above-median visceral adiposity
ultimately had a greater burden of subclinical
atherosclerosis, as indicated by coronary artery cal-
cium score (p < 0.05 for all BMI categories). Baseline
characteristics stratiﬁed by median subcutaneous fat
area (median 653.3 cm2/m) are shown in Online
Table 1. Notably, a greater degree of subcutaneous
adiposity was associated with a higher CRP and leptin
concentration (potentially markers of generalized
adiposity) and a lower coronary artery calcium score
(potentially suggesting a protective role for subcu-
taneous fat).FIGURE 3 Scatterplots and Spearman Correlation Between Height-I
Subcutaneous Fat Area With BMI and Weight
Visceral fat associations are shown on the left and subcutaneous fat ass
BMI ¼ body mass index.We further investigated the evolution of metabolic
risk factors over time from the baseline CT examina-
tion to the most contemporary MESA study visit,
stratiﬁed by above- or below-median VF area at
baseline CT examination (Figure 2). MESA partici-
pants with above-median VF area at baseline exami-
nation had higher weight, waist circumference, blood
pressure, and triglyceride and glucose concentration
and a lower HDL concentration at baseline and every
subsequent MESA visit (p < 0.05 for all). (This anal-
ysis was not adjusted for medication use or interval
weight changes.)
SINGLE AND LONGITUDINAL MEASURES OF
ADIPOSITY ARE ONLY MODESTLY ASSOCIATED
WITH BMI. BMI was closely associated with bothndexed Visceral Fat Area and Height-Indexed
ociations are on the right. Visceral fat area is expressed as cm2/m.
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1229subcutaneous adiposity and visceral adiposity
(Spearman R ¼ 0.63 for visceral, R ¼ 0.66 for subcu-
taneous, both p < 0.0001) (Figure 3), whereas total
body weight was more closely associated with
visceral than subcutaneous adiposity (R ¼ 0.56 for
visceral vs. R ¼ 0.41 for subcutaneous, both
p < 0.0001) (Figure 3). There was a weak association
between subcutaneous and VF burden at baseline
(Spearman R ¼ 0.26, p < 0.0001) (Figure 4).
In 253 patients with serial CT assessments for
both visceral and subcutaneous fat measures,
weight changes between CT examinations were
modest (median 0.3%, IQR: 3% to þ3%) compared
with changes in visceral (median 7%, IQR: 8%
to þ23%) and subcutaneous adipose tissue burden
(median 6%, IQR: 6% to þ19%) (Figure 5). Further-
more, the variability of changes in visceral or subcu-
taneous adiposity was considerably greater than the
variability of changes in weight (Figure 5), demon-
strating that even modest changes in weight may
result in large changes in fat distribution. The longi-
tudinal association between percent change in sub-
cutaneous fat and percent change in VF was modest
(Spearman R ¼ 0.44, p < 0.0001), suggesting that
changes in one fat depot do not completely mirror
changes in the other. Importantly, the correlation
between change in VF and change in weight was
stronger than for the baseline measures (Spearman
R ¼ 0.70, p < 0.0001).FIGURE 4 Scatterplot and Correlation Between Height-Indexed
Visceral Fat Area and Height-Indexed Subcutaneous Fat Area
The blue band represents 95% prediction limits for the
estimated regression line.A SINGLE MEASUREMENT OF VISCERAL ADIPOSITY
PREDICTS RISK OF INCIDENT METS INDEPENDENT
OF BMI, RACE, OR CARDIOMETABOLIC RISK. Over a
median follow-up of 6.2 years (IQR: 3.1 to 7.0 years),
203 (24%) of 862 participants without MetS at base-
line were newly diagnosed with MetS. In a discrete
unadjusted Cox regression (Online Table 2), subcu-
taneous fat area was associated with incident MetS
(HR: 1.16 per 100 cm2/m increase, 95% conﬁdence
interval [CI]: 1.12 to 1.20 per 100 cm2/m increase, p <
0.0001), although a similar increment in VF area
was associated with a higher hazard of MetS (HR:
1.31 per 100 cm2/m increase, 95% CI: 1.24 to 1.39 per
100 cm2/m increase, p < 0.0001). In addition, higher
adiponectin was associated with a lower risk of
MetS, whereas biomarkers of inﬂammation and
insulin resistance (fasting insulin, tumor necrosis
factor-a) were associated with an increased hazard
of MetS.
To investigate whether visceral and subcutaneous
fat burden are incrementally prognostic for MetS
beyond known cardiometabolic risk factors, we per-
formed incremental multivariable survival analysis
for incident MetS (Table 2). After adjustment for age,
sex, race, weight, smoking status, and MetS risk fac-
tors, height-indexed VF burden was associated with
incident MetS (HR: 1.28 per 100 cm2/m, 95% CI: 1.17 to
1.40 per 100 cm2/m, p < 0.0001) (Table 2, Model 3;
Figure 6) and effectively reclassiﬁed risk of incident
MetS (continuous net reclassiﬁcation index: 0.44,
95% CI: 0.29 to 0.66 vs. a fully adjusted clinical risk
model) (Table 2, Model 2). Subcutaneous adiposity
was signiﬁcant when added to a model containing VF
(HR: 1.08 per 100 cm2/m, 95% CI: 1.01 to 1.15 per 100
cm2/m, p ¼ 0.03) (Table 2, Model 4), although risk
reclassiﬁcation and model ﬁt were not appreciably
affected. Importantly, estimates of effect size for
visceral adiposity was similar in the fully adjusted
model compared with its univariable association
with MetS, suggesting that the association between
MetS and visceral adiposity is largely independent of
other cardiometabolic risk factors. Finally, there was
no evidence of modiﬁcation of the association be-
tween visceral or subcutaneous adiposity and inci-
dent MetS by race or sex.
Given the amount of imputation required for the
adiposity measures used, we also evaluated the
associations between VF and subcutaneous fat and
incident MetS excluding imputed data (Table 3).
Results were similar when imputed data were
excluded, speciﬁcally with signiﬁcant associations
between incident MetS and VF (HR: 1.38, 95% CI: 1.23
to 1.55, p < 0.0001) (Table 3, Model 4). In addition
to VF, glucose (p ¼ 0.0001), systolic blood pressure
FIGURE 5 Longitudinal Associations Between Percent Change in Visceral Fat, Subcutaneous Fat, and Weight
The underlying distribution of these changes is shown along each axis as a density function. Bivariate correlation between each measure is displayed on the plot with
corresponding p value (Spearman). The table provides the median and interquartile range (IQR) for change in each variable. SQ ¼ subcutaneous.
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1230(p ¼ 0.009), HDL concentration (p < 0.0001), and
weight (p ¼ 0.03) were also associated with MetS.
A GAIN IN VISCERAL ADIPOSITY IS ASSOCIATED
WITH INCIDENT METS INDEPENDENT OF CHANGE IN
WEIGHT OR CARDIOMETABOLIC RISK. Of the 862
MESA participants with a baseline CT scan and
without MetS, 253 participants had a repeat scan at
examination 4. Of these, 72 (28%) developed MetS. In
this longitudinal cohort, we determined whether
change in visceral and subcutaneous fat area is
associated with incident MetS, independent of base-
line weight or change in weight over time using
multivariable survival analysis (Table 4). Univariable
Cox regression models for incident MetS in this sub-
group are presented in Online Table 3. To address the
separate fat compartments separately (without the
inﬂuence of weight change), we added VF area and
weight change separately to our models for incident
MetS (Models 2 to 4). Change in weight was associ-
ated with incident MetS (HR: 1.33 per 5% increase;
95% CI: 1.02 to 1.72 per 5% increase, p ¼ 0.03),whereas a 5% change in VF area was associated with a
corresponding 5% increase in risk of MetS (95% CI:
1.01 to 1.08, p ¼ 0.02). Changes in subcutaneous fat
area were not associated with risk of MetS (p ¼ 0.77).
To understand the evolution of metabolic risk
factors over time in this cohort (e.g., components of
MetS), we examined the prevalence of metabolic risk
factors that qualify under the deﬁnition of MetS
(Table 5). Abdominal obesity (near 40%) and hyper-
tension (40% or higher) were prevalent at each ex-
amination in the population studied, whereas
dyslipidemia patterns were not as prevalent. How-
ever the prevalence of low HDL appeared to increase
over time.
DISCUSSION
In a multiracial, multiethnic, community-based pop-
ulation, we demonstrated that visceral adiposity is
associated with greater cardiometabolic risk regard-
less of BMI or race. We show that variability in both
TABLE 2 Multivariable Discrete Cox Survival Analysis for Incident Metabolic Syndrome in MESA Participants in the Study
Model 1 p Value Model 2 p Value Model 3 p Value Model 4 p Value
Degrees of freedom 9 15 16 17
AIC 1,173.2 Ref 1,090.9 <0.0001 1,065.2 <0.0001 1,062.4 0.09
LR chi-square 70.7 Ref 164.9 <0.0001 192.6 <0.0001 197.4 0.03
C-index 0.70 (0.66 to 0.74) N/A 0.78 (0.75 to 0.82) <0.0001 0.80 (0.77 to 0.83) 0.06 0.80 (0.77 to 0.83) 0.78
NRI N/A Ref 0.65 (0.50 to 0.80) <0.05 0.44 (0.29 to 0.60) <0.05 0.11 (0.05 to 0.27) >0.05
Relative IDI N/A Ref 0.92 (0.67 to 1.24) <0.05 0.19 (0.10 to 0.30) <0.05 0.02 (0.02 to 0.06) >0.05
Age, yrs 1.02 (1.00 to 1.04) 0.02 1.01 (0.98 to 1.03) 0.63 0.99 (0.97 to 1.02) 0.54 1.00 (0.97 to 1.02) 0.70
Female 2.23 (1.58 to 3.14) <0.0001 3.27 (2.10 to 5.08) <0.0001 4.72 (2.94 to 7.59) <0.0001 3.71 (2.20 to 6.25) <0.0001
Race
Caucasian American Ref Ref Ref Ref Ref Ref Ref Ref
Chinese American 1.42 (0.84 to 2.41) 0.19 0.91 (0.52 to 1.57) 0.72 1.01 (0.57 to 1.77) 0.98 0.98 (0.56 to 1.73) 0.95
African American 0.75 (0.50 to 1.14) 0.18 0.78 (0.50 to 1.21) 0.27 1.01 (0.64 to 1.60) 0.96 0.98 (0.62 to 1.56) 0.92
Hispanic 1.46 (0.99 to 2.16) 0.06 1.05 (0.69 to 1.59) 0.82 1.04 (0.68 to 1.59) 0.86 1.01 (0.66 to 1.54) 0.97
Weight, lbs 1.02 (1.02 to 1.03) <0.0001 1.01 (1.00 to 1.02) 0.19 1.01 (1.00 to 1.02) 0.31 1.00 (0.99 to 1.02) 0.45
Former smoker 0.90 (0.64 to 1.27) 0.56 1.08 (0.75 to 1.54) 0.69 1.10 (0.76 to 1.58) 0.61 1.14 (0.79 to 1.64) 0.49
Current smoker 1.19 (0.72 to 1.95) 0.50 1.17 (0.70 to 1.96) 0.56 1.24 (0.74 to 2.11) 0.42 1.23 (0.73 to 2.09) 0.44
Exercise per 1,000 MET 
min/week
0.98 (0.90 to 1.06) 0.57 1.00 (0.92 to 1.08) 0.98 1.00 (0.93 to 1.08) 0.96 1.00 (0.93 to 1.09) 0.93
Waist circumference, cm 1.03 (1.00 to 1.05) 0.02 1.01 (0.98 to 1.03) 0.56 0.99 (0.97 to 1.02) 0.68
Triglycerides, mg/dl 1.00 (1.00 to 1.01) 0.01 1.00 (1.00 to 1.01) 0.14 1.00 (1.00 to 1.01) 0.14
HDL, mg/dl 0.96 (0.95 to 0.98) <0.0001 0.97 (0.95 to 0.98) <0.0001 0.97 (0.95 to 0.98) <0.0001
SBP, mm Hg 1.02 (1.01 to 1.03) 0.006 1.02 (1.00 to 1.03) 0.01 1.02 (1.00 to 1.03) 0.02
DBP, mm Hg 1.01 (0.98 to 1.03) 0.54 1.01 (0.98 to 1.03) 0.66 1.01 (0.98 to 1.03) 0.55
Glucose, mg/dl 1.07 (1.04 to 1.10) <0.0001 1.06 (1.04 to 1.09) <0.0001 1.06 (1.03 to 1.09) <0.0001
Visceral fat per 100 cm2/m 1.28 (1.17 to 1.40) <0.0001 1.29 (1.18 to 1.41) <0.0001
Subcutaneous fat per
100 cm2/m
1.08 (1.01 to 1.15) 0.03
Values are hazard ratio (95% conﬁdence interval). “Ref” indicates referent category for comparisons. NRI and IDI statistics are calculated for each model relative to the model immediately
preceding (e.g., model 4 NRI represents model 4 vs. model 3). NRI, IDI, and C-index are calculated at second examination after computed tomography. Similar results were obtained when age,
weight, smoking, exercise, waist circumference, triglycerides, HDL, SBP, DBP, and glucose were modeled as time varying covariates as assessed at each MESA examination (except exercise,
which was not assessed at examination 4 and was assumed to be unchanged from examination 3).
AIC ¼ Akaike information criterion; DBP ¼ diastolic blood pressure; IDI ¼ integrated discrimination improvement; LR ¼ likelihood ratio; MET ¼ metabolic equivalent; NRI ¼ net reclassi-
ﬁcation index; SBP ¼ systolic blood pressure; other abbreviations as in Table 1.
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1231subcutaneous and VF stores is much greater than
variability in weight over time. Importantly, this
study within MESA is novel in that it speciﬁes that
changes in VF are strongly associated with incident
MetS and that the association between VF and inci-
dent MetS is greater for a similar increase in VF as
compared with subcutaneous fat. Effect modiﬁcation
by age, race, or sex was not present, suggesting that
the VF depot is critical in all groups to deﬁne car-
diometabolic risk. To our knowledge, these ﬁndings
represent the ﬁrst demonstration in a longitudinal,
community-based, multiethnic study of this link
between changes in visceral adiposity and car-
diometabolic risk, suggesting that visceral adiposity
is a BMI-independent, dynamic, mechanistic hall-
mark of cardiometabolic disease.
The notion that BMI may not fully deﬁne risk has
led to increased attention on aspects of obesity-
related cardiometabolic disease distinct from BMI
(14). Visceral adiposity has been suggested as acomplementary risk factor, given its pathogenic con-
sequences in animal models and the signiﬁcant
epidemiologic data suggesting its role in metabolic
dysfunction (1). In animal models of obesity,
dysfunctional visceral adipocytes represent a locus of
inﬂammation and insulin resistance (15,16). Indeed,
in humans, an improvement in insulin sensitivity is
associated with changes in VF (17), and inﬂammation
within visceral adipose tissue is associated with sys-
temic insulin resistance, inﬂammation, and endo-
thelial dysfunction (18). VF has been associated with
cardiovascular events (4), left ventricular remodeling
(19), and dysglycemia (2,3,20,21) in multiple large,
community-based cohorts (e.g., the Dallas, Jackson,
and Framingham Heart Studies). Most large,
community-based studies have demonstrated an as-
sociation between visceral adiposity, metabolic dis-
ease, and cardiovascular outcomes in obese (2) and
other select populations (e.g., African Americans
[3,21] or the Framingham area [4,20]). However,
TABLE 3 Discrete Cox Proportional Hazards Model for Incident MetS, Excluding Individuals With Imputed Data
Model 1 p Value Model 2 p Value Model 3 p Value Model 4 p Value
Degrees of freedom 9 15 16 17
AIC 865.8 Ref 797.8 <0.0001 769.1 <0.0001 771.1 1.00
LR chi-square 88.4 Ref 168.4 <0.0001 199.1 <0.0001 199.1 1.00
C-index 0.74 (0.69 to 0.78) N/A 0.81 (0.78 to 0.85) <0.0001 0.83 (0.80 to 0.86) 0.05 0.83 (0.8 to 0.86) 0.72
NRI N/A 0.72 (0.55 to 0.89) 0.52 (0.33 to 0.69) 0.11 (0.07 to 0.30)
Relative IDI N/A 0.59 (0.38 to 0.87) 0.13 (0.03 to 0.25) 0 (0 to 0)
Age, yrs 1.03 (1.01 to 1.05) 0.005 1.01 (0.99 to 1.04) 0.39 1.00 (0.97 to 1.03) 0.94 1.00 (0.97 to 1.03) 0.94
Female 3.20 (2.11 to 4.84) <0.0001 4.75 (2.81 to 8.02) <0.0001 7.88 (4.42 to 14.06) <0.0001 7.9 (3.92 to 15.93) <0.0001
Race
Caucasian American Ref Ref Ref Ref Ref Ref Ref Ref
Chinese American 2.47 (1.36 to 4.5) 0.003 1.60 (0.85 to 3.01) 0.14 1.89 (0.98 to 3.63) 0.06 1.89 (0.98 to 3.64) 0.06
African American 0.92 (0.57 to 1.47) 0.71 0.94 (0.57 to 1.56) 0.81 1.38 (0.80 to 2.36) 0.24 1.38 (0.8 to 2.38) 0.25
Hispanic 1.81 (1.12 to 2.92) 0.02 1.30 (0.78 to 2.17) 0.31 1.44 (0.86 to 2.43) 0.17 1.44 (0.85 to 2.45) 0.17
Weight, lbs 1.03 (1.02 to 1.04) <0.0001 1.02 (1.00 to 1.03) 0.01 1.02 (1.00 to 1.03) 0.02 1.02 (1.00 to 1.03) 0.03
Former smoker 1.11 (0.75 to 1.66) 0.60 1.42 (0.93 to 2.18) 0.10 1.57 (1.01 to 2.44) 0.05 1.57 (1.01 to 2.44) 0.05
Current smoker 1.25 (0.70 to 2.23) 0.45 1.35 (0.73 to 2.47) 0.34 1.50 (0.81 to 2.79) 0.20 1.50 (0.81 to 2.79) 0.20
Exercise per 1,000 MET  min/week 0.97 (0.89 to 1.05) 0.46 1.00 (0.92 to 1.09) 0.93 1.00 (0.92 to 1.10) 0.94 1.00 (0.92 to 1.10) 0.94
Waist circumference, cm 1.02 (0.99 to 1.05) 0.13 0.99 (0.96 to 1.02) 0.60 0.99 (0.95 to 1.03) 0.69
Triglycerides, mg/dl 1.00 (1.00 to 1.01) 0.02 1.00 (1.00 to 1.01) 0.31 1.00 (1.00 to 1.01) 0.31
HDL, mg/dl 0.96 (0.94 to 0.98) <0.0001 0.96 (0.94 to 0.98) <0.0001 0.96 (0.94 to 0.98) <0.0001
SBP, mm Hg 1.02 (1.01 to 1.03) 0.004 1.02 (1.01 to 1.03) 0.009 1.02 (1.01 to 1.03) 0.009
DBP, mm Hg 1.00 (0.97 to 1.03) 0.99 1.00 (0.97 to 1.03) 0.96 1.00 (0.97 to 1.03) 0.96
Glucose, mg/dl 1.07 (1.04 to 1.11) <0.0001 1.07 (1.03 to 1.10) 0.0001 1.07 (1.03 to 1.10) 0.0001
Visceral fat per 100 cm2/m 1.38 (1.23 to 1.54) <0.0001 1.38 (1.23 to 1.55) <0.0001
Subcutaneous fat per 100 cm2/m 1.00 (0.9 to 1.12) 0.99
Values are hazard ratio (95% conﬁdence interval). “Ref” indicates referent category for comparisons. NRI and IDI statistics are calculated for each model relative to the model immediately
preceding (e.g., model 4 NRI represents model 4 vs. model 3).
Abbreviations as in Tables 1 and 2.
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FIGURE 6 Cumulative Incidence of MetS by Discrete-Time Cox Model by Quartile of Visceral Adiposity
Adjustment for all covariates in the ﬁnal discrete-time Cox model (Model 3 in Table 2). Interquartile comparisons were signiﬁcant with p < 0.01
except for quartile 1 versus quartile 2 (p ¼ 0.30). Number at risk is listed under the x-axis. MetS ¼ metabolic syndrome.
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TABLE 4 Multivariable Discrete Cox Survival Analysis for Incident Metabolic Syndrome by Change in Visceral Adiposity in
All MESA Participants With Serial CT for Visceral Adiposity (n ¼ 253)
Model 1 p Value Model 2 p Value Model 3 p Value Model 4 p Value
Degrees of freedom 11 12 12 12
AIC 399.7 397 396.3 401.6
LR chi-square 57.2 Ref 61.8 <0.0001 62.5 <0.0001 57.2 0.04
C-index 0.77 (0.71 to 0.83) N/A 0.78 (0.72 to 0.84) 0.39 0.77 (0.71 to 0.83) 0.68 0.77 (0.71 to 0.83) 0.86
NRI N/A Ref 0.28 (0.03 to 0.55) >0.05 0.20 (0.09 to 0.49) >0.05 0.21 (0.49 to 0.11) >0.05
Relative IDI N/A Ref 0.10 (0.01 to 0.2) >0.05 0.11 (0.02 to 0.26) >0.05 0.01 (0.01 to 0.02) >0.05
Age, yrs 0.97 (0.94 to 1.00) 0.03 0.98 (0.95 to 1.01) 0.17 0.98 (0.95 to 1.01) 0.11 0.97 (0.94 to 1.00) 0.03
Female 0.87 (0.40 to 1.89) 0.72 0.89 (0.40 to 1.94) 0.76 0.88 (0.40 to 1.93) 0.74 0.82 (0.34 to 1.98) 0.65
Race
Caucasian American Ref Ref Ref Ref Ref Ref Ref Ref
Chinese American 0.51 (0.19 to 1.42) 0.2 0.6 (0.22 to 1.69) 0.34 0.59 (0.21 to 1.66) 0.32 0.51 (0.18 to 1.42) 0.2
African American 1.16 (0.56 to 2.39) 0.69 1.22 (0.59 to 2.53) 0.59 1.16 (0.56 to 2.39) 0.69 1.15 (0.55 to 2.37) 0.72
Hispanic 1.03 (0.49 to 2.16) 0.93 1.14 (0.54 to 2.41) 0.74 1.01 (0.47 to 2.13) 0.99 1.01 (0.48 to 2.15) 0.98
Former smoker 1.14 (0.64 to 2.04) 0.66 1.11 (0.62 to 2.00) 0.73 1.17 (0.65 to 2.10) 0.60 1.14 (0.64 to 2.03) 0.67
Current smoker 1.16 (0.47 to 2.86) 0.75 1.15 (0.47 to 2.85) 0.76 1.23 (0.49 to 3.05) 0.66 1.16 (0.47 to 2.85) 0.75
Weight, lbs 0.99 (0.98 to 1.00) 0.12 0.99 (0.98 to 1.00) 0.18 0.99 (0.98 to 1.00) 0.11 0.99 (0.97 to 1.00) 0.13
Number of MetS
components
2.67 (1.76 to 4.06) <0.0001 2.61 (1.72 to 3.96) <0.0001 2.47 (1.62 to 3.76) <0.0001 2.67 (1.75 to 4.05) <0.0001
Visceral fat per
100 cm2/m
1.24 (1.08 to 1.44) 0.003 1.23 (1.07 to 1.42) 0.004 1.29 (1.12 to 1.50) 0.0006 1.24 (1.07 to 1.43) 0.005
Subcutaneous fat per 100
cm2/m
1.08 (0.99 to 1.18) 0.10 1.08 (0.98 to 1.18) 0.11 1.10 (1.00 to 1.20) 0.05 1.09 (0.97 to 1.21) 0.14
DWeight, per 5% 1.33 (1.02 to 1.72) 0.033
DVisceral fat, per 5% 1.05 (1.01 to 1.08) 0.02
DSubcutaneous fat,
per 5%
1.00 (0.98 to 1.02) 0.77
Values are hazard ratio (95% conﬁdence interval). “Ref” indicates referent category for comparisons. NRI and IDI statistics are calculated for each model relative to the
base clinical model (Model 1).
Abbreviations as in Tables 1 and 2.
TABLE 5 Prevalence of Components of the Metabolic Syndrome at Each
MESA Study Visit in the Population Studied
Examination 1 Examination 2 Examination 3 Examination 4
Abdominal obesity 34.7 37.5 40.4 40.3
Elevated triglycerides 13.7 16.6 13.5 9.4
Low HDL 16.7 21.6 25.5 33.3
Hypertension 40.1 44.7 44.7 41.0
Hyperglycemia 0.0 2.3 2.8 3.9
Values are %.
Abbreviations as in Table 1.
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1233studies across racial lines and BMI in large American
cohorts as well as longitudinal evaluation of adipose
stores on cardiometabolic risk have not been
reported.
Small studies utilizing dietary interventions have
suggested that changes in visceral adiposity may be
linked to improvements in dysglycemia, dyslipide-
mia, and hypertension (22,23). In 1 of the largest
longitudinal studies, Matushita et al. (24) recently
reported results from 973 Japanese men with 2 serial
CT images over 3 years, demonstrating an increased
probability of dyslipidemia with a >50 cm2 increase in
VF area. In addition, these investigators have
demonstrated only a modest association between
increases in VF area and change in weight (25), sug-
gesting that generalized adiposity measures may not
reﬂect the VF compartment. Indeed, the observation
that modest weight loss produces a disproportionate
loss of VF (26) and durable relief of dyslipidemia (27)
and insulin resistance (28) may depend on sustaining
a reduction in visceral adiposity.
In this context, our study provides deﬁnitive sup-
port for an emerging hypothesis that BMI may notfully capture cardiometabolic risk: cross-sectional
associations between weight, BMI, and VF were
relatively modest. Furthermore, changes in weight
over time within our longitudinal cohort in MESA
were small relative to concomitant changes in visceral
or subcutaneous fat. These ﬁndings provide support
for the consideration of visceral adiposity as an
important, complementary clinical barometer of car-
diometabolic risk.
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1234STUDY LIMITATIONS. Our results should be viewed
in the context of its design. We did restrict our
study population to individuals with CT scans
available, and our longitudinal cohort was a smaller
sampling from the overall MESA cohort. Although
some of the CT results in the study were “imputed”
(mostly subcutaneous data), we found similar re-
sults when only nonimputed data was used, sug-
gesting the robustness of the associations we found.
In addition, the 1,511 MESA participants included in
this study were a subsample of the overall MESA
cohort, and potential for selection bias is present,
which we attempted to account for with adjustment
in regression. Though not the primary focus of our
work, the association of adiposity distribution with
coronary artery calciﬁcation is intriguing, and re-
quires further exploration with adjustments for co-
morbid illness to determine its signiﬁcance. Finally,
although we recognize that the effects of dietary
and behavioral changes on weight and adiposity
status are of great public health importance, MESA
is a prospective observational cohort; these impor-
tant clinical questions require ongoing randomized
studies.
CONCLUSIONS
In a large, multiracial, multiethnic population of
American adults, we demonstrated that despite
modest associations with traditional markersof adiposity, visceral adiposity stratiﬁes car-
diometabolic risk across BMI. Neither BMI nor waist
circumference—current clinical tools to estimate
obesity-related risk—were closely associated with VF,
and changes in weight were small compared with
concomitant changes in visceral or subcutaneous fat.
Finally, VF (both at a single time point and its change
over time) was strongly associated with incident
MetS, regardless of changes in weight or initial
weight, race, age, or sex. These results provide a much
needed extension of the growing recognition of the
pathophysiology of visceral adiposity in car-
diometabolic disease to a clinical arena and justify a
focus on VF as a modiﬁable risk factor for incident
MetS and downstream cardiovascular consequences
regardless of BMI.
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